Skip to content

Public FDA record

Z-0081-2019: BD FocalPoint Slide Profiler and BD FocalPoint GS Review Station; Catalog Nos. 490398, 490653, 491085, 49

Recall record Z-0081-2019 for Becton Dickinson & Co.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0081-2019
Company in FDA record
Becton Dickinson & Co.
FDA record creation date
Oct 5, 2018
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III

Reason stated in the source

The device may not function at the lower end (<15 deg. C) of the labeled operating temperatures. The instrument returns to normal operating conditions when environmental temperatures are at or above 15 deg. C. This issue has no potential to cause harm to either the patient or the operator. At the lower temperature, the instrument may fail to initialize, in which case slides would require manual screening. Therefore, no slides are screened by the device and no results can be released in error. The instrument labeling has been revised to indicate an operating temperature lower limit of 18 deg. C and operating humidity of 20 to 80% relative humidity.

Source facts

Action
On September 21, 2018, the firm,BD, notified its customers via a "MEDICAL DEVICE PRODUCT ADVISORY" letter. The letter described the product issue, provided corrected instrument labels, and advised customers to take the following actions: 1. Complete the attached Customer Response Form and return to the BD contact noted on the form via Email: BDRC2@bd.comor Fax to: 410-316-4258 whether or not you have any of the impacted material so that BD may acknowledge your receipt of this notification. 2. Using the enclosed label(s), affix a corrected instrument label onto each of your BD FocalPoint Slide Profiler instrument(s) over top of the existing label. The instrument label will be located on the back of your FocalPoint instrument. Note: The instrument labels for the BD FocalPoint GS Review Station are correct and do NOT need to be replaced. 3. Continue to use your FocalPoint per your normal facility procedures and guidelines. 4. Share this Advisory with all users of the FocalPoint within your facility to ensure awareness. 5. Place a copy of this letter in your manual for reference or access the revised Users Manual online a t www.e-labeling.eu/bdx500011292. BD has updated the FocalPoint users manual and labeling with the corrected environmental conditions. If you have further questions, please contact BD Customer Support at 800-638-8663 Monday Friday between 7:00am and 7:00pm (EST) in the United States.
Initiated
2018-09-21
Root cause
Under Investigation by firm
Terminated
2019-04-25
Distribution
Worldwide distribution: US (Nationwide) and to countries of: Korea, Australia, Japan, Malaysia, Canada, Brazil, and Belgium.
Recall number
Z-0081-2019
Recall status
Terminated
CDRH record ID
167442
FDA record created
2018-10-05
Recall event number
81097

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗